Abbott Laboratories Gross Profit 2012-2025 | ABT
Abbott Laboratories annual/quarterly gross profit history and growth rate from 2012 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Abbott Laboratories gross profit for the quarter ending September 30, 2025 was $6.294B, a 6.01% increase year-over-year.
- Abbott Laboratories gross profit for the twelve months ending September 30, 2025 was $24.504B, a 7.02% increase year-over-year.
- Abbott Laboratories annual gross profit for 2024 was $23.244B, a 5.01% increase from 2023.
- Abbott Laboratories annual gross profit for 2023 was $22.134B, a 9.7% decline from 2022.
- Abbott Laboratories annual gross profit for 2022 was $24.511B, a 0.11% decline from 2021.
|
Abbott Laboratories Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2024 | $23,244 |
| 2023 | $22,134 |
| 2022 | $24,511 |
| 2021 | $24,538 |
| 2020 | $19,605 |
| 2019 | $18,673 |
| 2018 | $17,872 |
| 2017 | $14,981 |
| 2016 | $11,759 |
| 2015 | $11,658 |
| 2014 | $11,029 |
| 2013 | $10,464 |
| 2012 | $10,151 |
| 2011 | $11,390 |
|
Abbott Laboratories Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-09-30 | $6,294 |
| 2025-06-30 | $6,288 |
| 2025-03-31 | $5,890 |
| 2024-12-31 | $6,032 |
| 2024-09-30 | $5,937 |
| 2024-06-30 | $5,774 |
| 2024-03-31 | $5,501 |
| 2023-12-31 | $5,685 |
| 2023-09-30 | $5,538 |
| 2023-06-30 | $5,495 |
| 2023-03-31 | $5,416 |
| 2022-12-31 | $5,498 |
| 2022-09-30 | $5,781 |
| 2022-06-30 | $6,324 |
| 2022-03-31 | $6,908 |
| 2021-12-31 | $6,702 |
| 2021-09-30 | $6,505 |
| 2021-06-30 | $5,276 |
| 2021-03-31 | $6,055 |
| 2020-12-31 | $6,208 |
| 2020-09-30 | $4,887 |
| 2020-06-30 | $4,065 |
| 2020-03-31 | $4,445 |
| 2019-12-31 | $4,880 |
| 2019-09-30 | $4,718 |
| 2019-06-30 | $4,700 |
| 2019-03-31 | $4,375 |
| 2018-12-31 | $4,574 |
| 2018-09-30 | $4,490 |
| 2018-06-30 | $4,485 |
| 2018-03-31 | $4,323 |
| 2017-12-31 | $4,307 |
| 2017-09-30 | $3,953 |
| 2017-06-30 | $3,448 |
| 2017-03-31 | $3,273 |
| 2016-12-31 | $2,951 |
| 2016-09-30 | $3,017 |
| 2016-06-30 | $3,046 |
| 2016-03-31 | $2,745 |
| 2015-12-31 | $2,982 |
| 2015-09-30 | $2,908 |
| 2015-06-30 | $2,952 |
| 2015-03-31 | $2,816 |
| 2014-12-31 | $3,019 |
| 2014-09-30 | $2,760 |
| 2014-06-30 | $2,769 |
| 2014-03-31 | $2,481 |
| 2013-12-31 | $2,047 |
| 2013-09-30 | $2,570 |
| 2013-06-30 | $2,901 |
| 2013-03-31 | $2,946 |
| 2012-12-31 | $1,507 |
| 2012-09-30 | $2,776 |
| 2012-06-30 | $2,943 |
| 2012-03-31 | $2,925 |
| 2011-12-31 | $6,539 |
| 2011-09-30 | $5,843 |
| 2011-06-30 | $5,746 |
| 2011-03-31 | $5,182 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $211.725B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EssilorLuxottica (ESLOY) | France | $146.103B | 0.00 |
| Stryker (SYK) | United States | $139.118B | 27.62 |
| Boston Scientific (BSX) | United States | $130.559B | 29.85 |
| Medtronic (MDT) | Ireland | $124.048B | 17.19 |
| Medline (MDLN) | United States | $57.961B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.907B | 0.00 |
| Agilent Technologies (A) | United States | $39.588B | 25.03 |
| ResMed (RMD) | United States | $37.591B | 26.02 |
| GE HealthCare Technologies (GEHC) | United States | $37.239B | 17.81 |
| Koninklijke Philips (PHG) | Netherlands | $28.483B | 18.60 |
| Terumo (TRUMY) | Japan | $20.476B | 23.05 |
| Insulet (PODD) | United States | $20.239B | 62.82 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.303B | 10.79 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.893B | 0.00 |
| Baxter (BAX) | United States | $10.338B | 8.34 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.457B | 30.41 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.261B | 12.98 |
| Envista Holdings (NVST) | United States | $4.150B | 23.81 |
| BillionToOne (BLLN) | United States | $4.061B | 0.00 |
| ICU Medical (ICUI) | United States | $3.855B | 24.48 |
| Haemonetics (HAE) | United States | $3.378B | 15.04 |
| Prestige Consumer Healthcare (PBH) | United States | $3.131B | 14.28 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.255B | 14.50 |
| Perrigo (PRGO) | Ireland | $2.068B | 5.18 |
| Neogen (NEOG) | United States | $2.012B | 44.05 |
| LeMaitre Vascular (LMAT) | United States | $2.002B | 40.31 |
| AtriCure (ATRC) | United States | $1.942B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.805B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 73.55 |
| Phibro Animal Health (PAHC) | United States | $1.665B | 16.63 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.471B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.437B | 20.80 |
| Kestra Medical Technologies (KMTS) | United States | $1.333B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.176B | 348.86 |
| Capricor Therapeutics (CAPR) | United States | $1.113B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.062B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.002B | 0.00 |
| InMode (INMD) | Israel | $0.881B | 9.96 |
| Valneva SE (VALN) | France | $0.867B | 0.00 |
| Omeros (OMER) | United States | $0.852B | 0.00 |
| CeriBell (CBLL) | United States | $0.814B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.578B | 15.67 |
| Cerus (CERS) | United States | $0.499B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.479B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Brainsway (BWAY) | Israel | $0.454B | 77.27 |
| Canopy Growth (CGC) | Canada | $0.438B | 0.00 |
| Quanterix (QTRX) | United States | $0.346B | 0.00 |
| Evolus (EOLS) | United States | $0.337B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.279B | 22.21 |
| TriSalus Life Sciences (TLSI) | United States | $0.276B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.00 |
| TerrAscend (TSNDF) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.232B | 0.00 |
| High Tide (HITI) | Canada | $0.224B | 0.00 |
| Organigram Global (OGI) | Canada | $0.218B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanara MedTech (SMTI) | United States | $0.203B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.196B | 17.27 |
| Accendra Health (ACH) | United States | $0.195B | 1.95 |
| OraSure Technologies (OSUR) | United States | $0.193B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.192B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| Apyx Medical (APYX) | United States | $0.153B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.116B | 16.79 |
| Jushi Holdings (JUSHF) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Exagen (XGN) | United States | $0.106B | 0.00 |
| Biote (BTMD) | United States | $0.106B | 4.64 |
| Sharps Technology (STSS) | United States | $0.069B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 24.46 |
| Nephros (NEPH) | United States | $0.048B | 34.46 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Veru (VERU) | United States | $0.043B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.031B | 15.67 |
| Jin Medical (ZJYL) | China | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Bonk (BNKK) | United States | $0.018B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |